Ubs Group Ag Immatics N.V. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Immatics N.V. stock. As of the latest transaction made, Ubs Group Ag holds 3,762 shares of IMTX stock, worth $44,128. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,762

Previous 4,156 9.48%

Holding current value

$44,128

Previous $43,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$9.78 - $13.49 $3,853 - $5,315	-394 Reduced 9.48%	3,762 $43,000
Q1 2024 May 13, 2024	SELL	$10.23 - $12.94 $66,464 - $84,071	-6,497 Reduced 60.99%	4,156 $43,000
Q4 2023 Feb 09, 2024	SELL	$7.36 - $10.89 $118,459 - $175,274	-16,095 Reduced 60.17%	10,653 $112,000
Q3 2023 Nov 09, 2023	BUY	$11.01 - $12.62 $244,950 - $280,769	22,248 Added 494.4%	26,748 $309,000
Q2 2023 Aug 11, 2023	SELL	$5.92 - $12.72 $6,529 - $14,030	-1,103 Reduced 19.69%	4,500 $51,000
Q1 2023 May 12, 2023	SELL	$6.74 - $9.44 $17,827 - $24,968	-2,645 Reduced 32.07%	5,603 $38,000
Q4 2022 Feb 08, 2023	BUY	$8.05 - $11.58 $53,073 - $76,346	6,593 Added 398.37%	8,248 $71,000
Q3 2022 Nov 10, 2022	SELL	$3.31 - $13.06 $13,925 - $54,943	-4,207 Reduced 71.77%	1,655 $17,000
Q2 2022 Aug 10, 2022	BUY	$6.0 - $9.37 $24,522 - $38,295	4,087 Added 230.25%	5,862 $51,000
Q1 2022 May 16, 2022	SELL	$6.64 - $12.85 $8,512 - $16,473	-1,282 Reduced 41.94%	1,775 $14,000
Q4 2021 Feb 14, 2022	SELL	$10.81 - $14.38 $464 - $618	-43 Reduced 1.39%	3,057 $41,000
Q3 2021 Nov 15, 2021	BUY	$11.58 - $15.46 $14,729 - $19,665	1,272 Added 69.58%	3,100 $40,000
Q2 2021 Aug 13, 2021	BUY	$10.43 - $12.81 $1,230 - $1,511	118 Added 6.9%	1,828 $21,000
Q1 2021 May 12, 2021	BUY	$10.24 - $14.6 $17,510 - $24,966	1,710 New	1,710 $19,000

Others Institutions Holding IMTX

# of Institutions

Shares Held

76.6M

Call Options Held

571K

Put Options Held

210K

View Full List

About Immatics N.V.

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $894M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

More about IMTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account